Scynexis Inc Expected To Post A Loss Of 17 Cents A Share: Earnings Preview
02/05/2025 12:04
SCYNEXIS Inc SCYX.OQ SCYX.O is expected to show a fall in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025 The Jersey City New Jersey-based company is expected to report a 85.0% decrease in revenue to $205.5 thousand from $1.37 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data. LSEG's mean analyst estimate for SCYNEXIS Inc is for a loss of 17 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for SCYNEXIS Inc is $5.00, above its last closing price of $0.98. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.22 | -0.09 | Beat | 59.1 | |
| Sep. 30 2024 | -0.07 | -0.07 | -0.06 | Beat | 18.9 |
| Jun. 30 2024 | -0.20 | -0.20 | -0.30 | Missed | -48.5 |
| Mar. 31 2024 | -0.19 | -0.20 | 0.01 | Beat | 105.1 |
| Dec. 31 2023 | -0.20 | -0.39 | Missed | -95 | |
| Sep. 30 2023 | -0.17 | -0.15 | -0.04 | Beat | 72.6 |
| Jun. 30 2023 | 1.61 | 1.55 | 2.46 | Beat | 58.9 |
| Mar. 31 2023 | -0.28 | -0.28 | -0.71 | Missed | -155.4 |
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview